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BCG = bacille Calmette–Guérin; ESAT = early secreted antigen; HIV = human immunodeficiency virus; LACK = Leishmania homolog of receptors
for activated C-kinase; MHC = major histocompatibility complex; Th = T-helper (cell); TLR = toll-like receptor; TNF = tumor necrosis factor.
Available online http://respiratory-research.com/content/2/3/157
Introduction
Tuberculosis remains one of the most important infectious
diseases in the world [1]. It is estimated that 2 billion
persons on the planet harbor latent tuberculosis infection.
Eight to 12 million new cases of active tuberculosis occur
each year, and at any given time there are approximately 16
million persons with active tuberculosis in the world. These
cases result in 2–3 million deaths annually, making tuber-
culosis the single leading cause of death of any infectious
disease. These figures are even more staggering when one
realizes that the vast majority of cases of tuberculosis are
curable with currently available medications.
Although there have been some notable success stories in
recent years in controlling tuberculosis and reducing case
rates (mostly in wealthy countries such as the USA), there
is little cause for optimism in parts of the world where
poverty, political disorganization, and access to care
remain major obstacles to global tuberculosis control. In
fact, with the continued spread of the human immunodefi-
ciency virus (HIV) epidemic, particularly in Africa and Asia,
and the emergence of multidrug-resistant tuberculosis in
many parts of the world, there will continue to be signifi-
cant upwards pressure on the number of tuberculosis
cases in the world for the next several years. This increas-
ing pressure occurs in the context of what has been a long
stagnant period in tuberculosis drug development. No
new class of antituberculosis drugs has been introduced
since the rifamycins came into use 30 years ago.
The clinical manifestations of infectious disease are
caused by the balance between virulence factors that are
elaborated by the invading microbe, and the host immune
response that the body mounts to defend itself. In many
infectious syndromes, virulence factors are responsible for
most of the disease manifestations. Examples include toxic
shock syndrome and Gram-negative sepsis, in which
lipopolysaccharide released by invading bacteria sets off a
Review
Recent advances in our understanding of human host responses
to tuberculosis
Neil W Schluger
Associate Professor of Medicine and Public Health, Columbia University College of Physicians and Surgeons, New York, USA
Correspondence: Neil W Schluger, MD, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia Presbyterian Medical Center, PH-8
Center, 630 West 168th Street, New York, NY 10032, USA. Tel: +1 212 305 9817; fax: +1 212 342 5272; e-mail: ns311@columbia.edu
Abstract
Tuberculosis remains one of the world’s greatest public health challenges: 2 billion persons have latent
infection, 8 million people develop active tuberculosis annually, and 2–3 million die. Recently,
significant advances in our understanding of the human immune response against tuberculosis have
occurred. The present review focuses on recent work in macrophage and T-cell biology that sheds
light on the human immune response to tuberculosis. The role of key cytokines such as interferon-g is
discussed, as is the role of CD4+ and CD8+ T cells in immune regulation in tuberculosis, particularly
with regard to implications for vaccine development and evaluation.
Keywords: CD4+ cell, CD8+ cell, immunity, interferon, tuberculosis
Received: 15 February 2001
Revisions requested: 1 March 2001
Revisions received: 2 March 2001
Accepted: 2 March 2001
Published: 29 March 2001
Respir Res 2001, 2:157–163
This article may contain supplementary data which can only be found
online at http://respiratory-research.com/content/2/3/157
© 2001 BioMed Central Ltd
(Print ISSN 1465-9921; Online ISSN 1465-993X)Respiratory Research    Vol 2 No 3 Schluger
whole cascade of inflammatory events. On the other hand,
in many infectious syndromes relatively avirulent organ-
isms cause disease mainly by forcing the host to respond
in one or more of a variety of ways that result in specific
manifestations of disease. Such would seem to be the
case in leprosy, for example. Mycobacterium leprae
appears capable of eliciting two distinct host immune
responses that result in the two different clinical manifes-
tations of the disease [2,3]: tuberculoid leprosy and lepro-
matous leprosy.
Little is known about virulence factors of Mycobacterium
tuberculosis. Interesting studies have recently been
reported that describe the mechanisms that underlie
behaviors such as cording, and a body of work describing
the relationship between sigma factors and mycobacterial
latency has also been done [4–8]. During the next few
years it is likely that significant advances will be made in
our understanding of mycobacterial virulence as a result of
projects such as the sequencing of the M tuberculosis
genome (now already complete for several laboratory and
clinical isolates), as well as advances in the field of
mycobacterial genetics. Such advances in our under-
standing of the basic biology of M tuberculosis should aid
in the design and evaluation of new therapeutic drugs.
Understanding human host immunity to tuberculosis is
important for several reasons. Paramount among these,
however, must be that only through a thorough knowledge
of how tuberculosis is recognized and controlled by the
immune system will we be able to design and evaluate
new vaccine candidates. In the long run, vaccination still
represents an important goal in tuberculosis control, and
is perhaps the best hope for ultimate eradication of this
disease.
The challenges in tuberculosis vaccine development are
enormous. Two major features of clinical tuberculosis
frame the challenge of vaccine development. The first is
that, as noted above, 2 billion persons are already infected
with  M tuberculosis, so that a vaccine might need to
protect against reactivation rather than infection. The
second is that, unlike many other infections (particularly
viral infections), the extent to which natural immunity to
tuberculosis exists is not clear. Whereas patients who
recover from chicken pox have lifelong immunity against
reinfection, patients who have recovered from tuberculosis
may be subject to reinfection. This has been demonstrated
in patients with HIV who clearly are significantly immuno-
compromised, but recent data indicate that reinfection
may also occur in patients without HIV infection or appar-
ent immunosuppression [9,10]. This may be an infrequent
occurrence, but it does raise the possibility (as recently
pointed out by Kaufmann [11]) that we may be faced with
the challenge of designing a vaccine that needs to provide
better than natural immunity!
In addition to aiding the effort to develop a novel vaccine
for tuberculosis, understanding the human immune
response might also point to novel immunotherapeutic
approaches to treatment of tuberculosis, particularly in the
setting of multidrug resistance, in which there are often no
viable chemotherapy options.
During the past several years much has been learned
about the human immune response to tuberculosis. In fact,
the conduct of direct experiments using human tissues, as
well as in vivo studies of human immune responses to
tuberculosis, represents a major advance in our under-
standing of the pathogenesis of this disease. Although
animal models of tuberculosis have taught us (and will
continue to teach us) a great deal about the pathogenesis
of this disease, it remains the case that there is no com-
pletely satisfactory animal model of human tuberculosis.
The present review focuses wherever possible on studies
of the human host response to tuberculosis, making refer-
ence to animal studies only when they are particularly
instructive or are the only good data available. Attention is
directed mainly to macrophage and T-lymphocyte biology.
Genetic susceptibility to tuberculosis
infection and disease
Several observational studies indicate that certain popula-
tions appear to exhibit unusual susceptibility to tuberculo-
sis, and it is likely that to a certain degree this
susceptibility has a genetic basis. It appears that tubercu-
losis was a disease that may have originated largely in
Western Europe, and was then transmitted to other parts
of the world through migration, exploration, and coloniza-
tion. If this indeed happened, then there would have been
relatively little selection pressure favoring resistance to
tuberculosis infection and disease in regions such as
Africa and Asia, and the disease would have spread easily
among these populations. There is relatively convincing
evidence that Eskimos, African-Americans, and other pop-
ulations do seem to exhibit heightened susceptibility (or
conversely, that populations descended from white Euro-
pean stock have a degree of innate resistance) [12]. The
most recently described example of this susceptibility may
be that of the Yanomami Indians of Peru [13], a tribe that
had remained extremely isolated for thousands of years
until being ‘discovered’ by anthropologists a few decades
ago. It is almost certain that tuberculosis had not occurred
among the Yanomami previously, but soon after contact
with outsiders a tuberculosis epidemic swept through the
tribe with unusual ferocity and lethality.
Despite the apparent susceptibility of various populations,
the actual genetic basis for vulnerability to tuberculosis is
obscure; susceptibility is probably a polygenetic predispo-
sition that has major interactions with the environment.
Furthermore, whereas animal models allow the study of
risk of actual infection, human studies necessarily focus onc
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the risk of progression to active disease in patients who
have already been infected, because it is difficult if not
impossible to determine clinically when and how an indi-
vidual initially developed latent infection.
Polymorphisms in several candidate genes have been
linked to relatively increased risk for tuberculosis disease
[14]. These genes include several human leukocyte
antigen loci, vitamin D receptors, and the gene for the
natural resistance-associated macrophage protein
(NRAMP). NRAMP presents an intriguing although some-
what confusing story. Originally, NRAMP was determined
to control susceptibility to infection in a strain of mice
known as Ity/Lsh/Bcg, which are extremely vulnerable to
disease caused by intracellular pathogens such as salmo-
nella, leishmania, and Mycobacterium bovis. However,
later work [15–18] cast doubt on the importance of this
gene (which produces a membrane-bound transport
protein of uncertain function) in protection against murine
tuberculosis. A human homolog for NRAMP was quickly
identified, and a study was reported that implicated a link
between certain NRAMP polymorphisms and the risk of
developing active tuberculosis among patients with latent
infection in West Africa [19]. The relative risk of develop-
ing active tuberculosis in among those with susceptible
genotypes was about 1.8, and interestingly the dominant
genotype in humans appeared to be susceptible, whereas
in mice it was resistant.
Immunologic defense against infection and
disease caused by M tuberculosis
It is generally felt that only the cellular immune system
plays a significant role in host defense against M tubercu-
losis [20]. Although antibodies are made against several
mycobacterial products, including cell-wall components,
there is as yet little evidence that humoral immunity is clini-
cally important. Studies of antibody production in
response to tuberculosis mainly have application in the
continuing effort to develop a serologic test for tuberculo-
sis, although some still feel that humoral immunity does in
fact play a significant role in actual host defense [21–23].
Initial defense against Mtuberculosis infection:
phagocytosis by macrophages
After evading the mechanical defenses of the upper respi-
ratory tree, respiratory droplet nuclei that contain viable
M tuberculosis organisms make their way into the distal
regions of the lung. Here, they come into contact with the
resident immune cell of the lung: the alveolar macrophage.
Uptake of M tuberculosis by macrophages represents the
first major host–pathogen interaction in tuberculosis. Pre-
sumably, there are persons in whom macrophages, upon
initial contact with M tuberculosis, are able to kill the
pathogen directly and completely eliminate it, never allow-
ing a latent stage of infection to develop. Although there is
of course no direct evidence of this, there are persons
with repeated exposure to cases of active tuberculosis
who neither develop positive tuberculin skin tests or active
tuberculosis, providing indirect evidence that such an
outcome is possible.
Binding of M tuberculosis to macrophages can be accom-
plished by a number of mechanisms. It has been demon-
strated [24–28] that complement receptors, mannose
receptors, surfactant receptors, scavenger receptors, and
others are capable of mediating this initial interaction. Most
recently, attention has focused on the role of toll-like recep-
tors (TLRs) in mediating the uptake of mycobacteria by
macrophages. Brightbill et al [29] demonstrated that, when
TLRs are activated by lipoproteins that are contained within
the  M tuberculosis cell wall, interleukin-12 production is
stimulated in THP-1 cells, a human macrophage-like cell
line. Interleukin-12 is an important pro-inflammatory
cytokine in host responses against tuberculosis, and the
TLR-mediated stimulation of interleukin-12 was itself medi-
ated through the transcription factor nuclear factor-kB.
Furthermore, TLR-mediated interleukin-12 production also
resulted in increased production of nitric oxide synthase
and nitric oxide production, which are important steps in
intracellular killing of M tuberculosis. Thus, engagement of
TLRs may be an important triggering step in the host
response against M tuberculosis.
The complexities of the TLR system have been amplified
by the work of Means et al [30] and Underhill and cowork-
ers [31,32]. These groups have carried out experiments
that dissect the relative contributions of the TLR2 and
TLR4 subsets of receptors when they are activated by dif-
ferent mycobacterial components. Both of these receptors
can be activated by live M tuberculosis, although different
bacterial components can activate each, and it is possible
that the different subclasses of receptors in turn stimulate
different facets of the immune response. For example, the
work of Underhill and coworkers [31,32] showed that ara-
binogalactan and peptidoglycan can increase tumor
necrosis factor (TNF)-a production through activation of
TLR2, but that mannose lipoarabinomannan did not. Inter-
estingly, nonreceptor surface molecules, such as CD43
(leukosialin/sialophorin), may also be key components of
the initiation of the immune response, because it has
recently been demonstrated that CD43 is involved in the
stable interaction of mycobacteria with other cell-surface
receptors that increase TNF-a production.
A major puzzle in the biology of tuberculosis is the estab-
lishment and persistence of the latent state of infection, in
which a small number of mycobacteria can remain
dormant but viable for many years. An interesting recent
study sheds light on this phenomenon. Gatfield and
Pieters [33] demonstrated that cholesterol is required for
uptake of mycobacteria into cells. After demonstrating that
cholesterol accumulated at the site of phagocytosis in
Available online http://respiratory-research.com/content/2/3/157(murine) macrophages, the investigators depleted cellular
cholesterol by inhibiting cholesterol synthesis and extract-
ing residual cholesterol from the plasma membrane. After
this, uptake of mycobacteria was reduced by 85%.
Cholesterol was also important in mediating the phagosomal
association of a molecule termed tryptophane aspartate-
containing coat protein, which prevents the degradation of
mycobacteria in lysomes.
Many bacterial factors are also involved in establishing the
latent state of infection. Although a thorough description of
mycobacterial biology related to latency and persistence
is beyond the scope of the present review, it is likely that a
balance of host immune responses and microbial factors
are involved in initiating and maintaining the dormant state.
In addition to phagocytosis, macrophages contribute further
to the immune response both by inhibiting growth or by
killing mycobacteria (see below), and by secreting cytokines
that further amplify the immune response. One such
cytokine is TNF-a, which appears to play a central role in
granuloma formation. Although the importance of TNF in
granuloma formation (and the exact role of the granuloma
itself in host defense) in humans has not been directly
assessed, animals that lack TNF showed markedly impaired
granuloma formation and died from overwhelming mycobac-
terial disease soon after becoming infected [34–36].
T cells in the host immune response
During the past several years it has become apparent that
T cells play a major role in the tuberculosis host response
in humans. This is nowhere more obvious than in patients
with HIV infection, in whom tuberculosis is a major
pathogen and often represents the acquired immune defi-
ciency disease-defining illness. Patients with HIV infec-
tion and latent tuberculosis infection develop active
tuberculosis at a rate that approaches 10% per year, as
opposed to 10% over the lifetime of a person with an
intact immune system.
Initial studies in humans focused on the role of CD4+
T cells in tuberculosis host defense, but in recent years a
great deal of attention has been devoted to CD8+ T cells,
particularly with regard to protective immunity.
CD4+ T lymphocytes
CD4+ T cells, also called T-helper (Th) cells, provide T-cell
help to other immune cells, and thus amplify the immune
response. There is now substantial evidence in humans
that Th cells can display at least two phenotypes – Th1
and Th2 – which can be described mainly by the pattern
of cytokines secreted [3]. The hallmark of Th1 cells is the
production of interferon-g, which has been shown during
the past several years to be a key effector cytokine in the
host response against tuberculosis. Th2 cells primarily
secrete the cytokines interleukin-4, interleukin-5, and inter-
leukin-10, cytokines that in general have not been shown
to play a major role in tuberculosis host immunity.
A major aspect of the importance of Th1 cells in tubercu-
losis host defense is their ability to secrete interferon-g.
Although CD8+ T cells (and perhaps macrophages as
well) also secrete this cytokine (see below), CD4+ cells
probably constitute the major source of this protein. A
substantial body of evidence now exists that demonstrates
that interferon-g plays a key role in defense against tuber-
culosis [20]. This pro-inflammatory cytokine has multiple
beneficial actions, many of which are centered on its
effects on macrophage biology. Production of both reac-
tive oxygen intermediates and reactive nitrogen intermedi-
ates by macrophages are stimulated by interferon-g. Both
reactive oxygen intermediate and reactive nitrogen inter-
mediate pathways have been implicated in intracellular
growth inhibition and/or killing of mycobacteria, although
there is debate about which pathway, if either, is critical in
this regard [37–40].
Interferon-g has several other effects on macrophages,
including the increased expression of major histocompati-
bility complex (MHC) class II molecules, thus leading to
increased antigen presentation and further amplification of
the immune response. Interferon-g may also upregulate
expression and secretion of TNF from macrophages.
In human tuberculosis, the importance of interferon-g is
clear. Individuals who lack the ability to produce inter-
feron-g on a genetic basis, or who cannot respond to it or
lack the receptor for it, are susceptible to severe systemic
infection with mycobacterial species that do not usually
cause significant disease in immunocompetent individuals
[41,42]. In humans with pulmonary tuberculosis, we have
shown [43] that a lymphocytic alveolitis characterized by
significant local production of interferon-g is associated
with clinically and radiographically mild disease, whereas
patients who do not mount this type of response are much
more likely to have sputum smear-positive, cavitary
disease. In addition, when exogenous interferon-g was
administered by aerosol to a group of patients with mul-
tidrug-resistant tuberculosis who had failed medical
therapy, clinical and radiographic improvement was con-
sistently noted [44]. The improvement seemed to persist
only as long as the course of treatment.
Because an interferon-g-producing Th1 response is clearly
crucial in effective tuberculosis host defense, the genera-
tion and maintenance of such a response has generated
considerable interest. It is in the generation of this
response that the keys to understanding and development
of an effective vaccine are likely to be hidden. Recent
studies using Leishmania major (an intracellular pathogen
that is controlled by a Th1 response in a manner similar to
that for tuberculosis) as a model pathogen have implicated
Respiratory Research    Vol 2 No 3 Schlugerthe involvement of some key cytokines and antigens [45].
In a murine model of leishmaniasis, it appears that only
certain L major antigens (in this instance a protein termed
Leishmania homolog of receptors for activated C-kinase
[LACK]) are capable of stimulating protective immunity
when given in the form of a DNA vaccine before challenge
with live pathogen. In addition, LACK DNA vaccination
alone does not confer protective immunity; a persistent
source of interleukin-12 was also required to establish a
Th1-type protective immune response. Interleukin-12 has
previously and definitely been shown to be a potent
inducer of interferon-g from many different cell types.
As bacille Calmette–Guérin (BCG) vaccine provides only
limited protection in humans, eliciting longer lived immu-
nity by linking interleukin-12-inducing strategies with
immunogenic mycobacterial proteins in a vaccine may be
efficacious. Indeed, several groups are pursing this. When
interleukin-12 was used as an adjuvant to BCG vaccine in
a murine model, enhanced protection was noted [46].
BCG vaccination alone resulted in a 1–2 log decrease in
bacterial burden after challenge with virulent M tuberculo-
sis, as compared with unvaccinated animals. Adding inter-
leukin-12 to the vaccine decreased bacterial loads twofold
to fivefold further. In addition, interferon-g gene expression
and protein production in spleen cells were increased
when interleukin-12 was added to BCG alone. In work by
Russo et al [47], tuberculosis-naïve T cells were primed in
vitro with intact mycobacteria or only the antigenic protein
Ag85. This elicited a Th1 response when cells were
rechallenged with mycobacteria. Adding interleukin-12 to
the priming enhanced the magnitude of the Th1 response;
interestingly, however, antibody to interleukin-12 did not
eliminate the response. This reflects the complex nature of
this phenomenon. Most recently, Marchant et al [48]
demonstrated that Th-null (Th0), purified protein derivative-
specific T-cell clones from patients with active tuberculosis
could be coaxed into a Th1 phenotype by the in vitro
administration of interleukin-12. This provides further evi-
dence for the importance and potential clinical utility of this
cytokine in vaccine development, or perhaps as adjunctive
immunotherapy.
CD8+ T lymphocytes
During the past 3–4 years, increasing attention has turned
to CD8+ T cells and their involvement in mycobacterial
host defense, and there is substantial evidence that these
cells play a major role [49,50]. CD8+ T cells are capable
of producing significant amounts of interferon-g, and a Tc1
phenotype, similar to a Th1 phenotype, is the predominant
type of CD8+ cell; in addition, they are cytotoxic T cells
and probably play a significant role in true protective
immunity of the type conferred by vaccination. CD8+
T cells recognize processed peptide fragments that are
presented on cell surfaces in the context of MHC class I
molecules (expressed on most cells in the body), which
then bind to the T-cell receptor. CD8+ T cells can also
bind the CD1 molecule, a more recently described mode
of antigen presentation, which is present on the surface of
professional antigen-presenting cells. CD8+ T cells have
clearly been identified that recognize alveolar
macrophages and dendritic cells, which are of course pro-
fessional antigen-presenting cells.
CD8+ cells can be both cytotoxic, causing lysis of infected
target cells such as monocytes and macrophages, and
microbicidal, causing death of intracellular pathogens
directly. When macrophages release the intracellular
pathogens, those pathogens can then be killed by activated
effector cells that have been recruited through a variety of
signals. This is an example of cell-mediated cytotoxicity.
Direct microbicidal activity is also possessed by CD8+
T cells. A granule-associated T-cell protein called granulysin
can be secreted by CD8+ cells, and can kill extracellular
Mtuberculosis directly. In concert with perforin, another
T-cell product, it may also kill intracellular mycobacteria.
Lewinsohn et al [51] characterized human CD8+ T cells
that are reactive with M tuberculosis-infected antigen-
presenting cells. These investigators showed that
M tuberculosis-reactive CD+ T cells are found mainly in
persons with latent tuberculosis infection, and in
response to stimulation with M tuberculosis-infected
target cells produced significant amounts of interferon-g.
Interestingly, recognition of infected cells by CD8+
T cells was not restricted by MHC class I A, B, or C
alleles, or by CD1. These tuberculosis-specific CD8+
cells recognized an antigen that is generated in the pro-
teasome, although it is not transported through the
Golgi–endoplasmic reticulum apparatus.
Smith et al [52] further characterized the role of tuberculo-
sis-specific CD8+ T cells in humans. When taken from
persons who had received BCG vaccination and restimu-
lated with live M bovis BCG, CD8+ T cells produced sub-
stantial amounts of interferon-g and TNF-a. In fact, more of
these cytokines were produced when cells were stimu-
lated with M bovis BCG than with purified protein deriva-
tive. Perforin was also expressed by these CD8+ cells,
which demonstrated marked cytotoxic ability against cells
infected with M bovis BCG, M tuberculosis antigens 85A
and B, and to a lesser extent the 19 kDa or 38 kDa tuber-
culosis proteins. No significant cytotoxic activity of CD8+
cells from BCG-vaccinated persons was directed against
target cells infected with the early secreted M tuberculo-
sis antigen (ESAT)-6. This is of interest because recent
data from the genomic sequences of several mycobacteria
indicate that the gene for ESAT-6 is absent in the vaccine
strain of BCG, and is highly specific for M tuberculosis.
This finding provides further evidence for the specificity of
CD8+ T-cell responses. Unlike Lewinsohn et al [51], Smith
et al [52] determined that the cytotoxic activity of the
Available online http://respiratory-research.com/content/2/3/157
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pathways. As Lewinsohn et al studied presentation of
Mtuberculosis  rather than that of M bovis, the circumven-
tion of MHC class I pathways might represent a virulence
strategy of M tuberculosis.
Pathan and coworkers [53,54] studied tuberculin skin
test-positive household contacts and persons with inac-
tive ‘self-healed’ pulmonary tuberculosis, and showed
that a nonamer epitope from the M tuberculosis protein
ESAT-6 could be recognized by CD8+ T cells for long
periods of time after infection. These data suggest that
long-lived specific CD8+ T-cell responses are associated
with apparent control of M tuberculosis infection in
humans.
Conclusion
Recent years have seen an explosion in knowledge
regarding the human host response to tuberculosis and
disease. The importance of cytokines such as
interferon-g has been established beyond doubt, and the
role of important lymphocyte effector cells has begun to
be elucidated. Major unanswered questions remain,
however. The relative importance of CD4+ and CD8+
T cells in the host response must be clarified, although
gathering evidence suggests that the former play a
greater role in the immune response against active
disease and that the latter are more involved in control-
ling latent infection. The specific M tuberculosis antigens
that are capable of provoking the most protective
immune responses remain to be identified, although
progress is being made, and elucidation of the entire
genomic sequences of several pathogenic strains of
M tuberculosis and related strains should aid this effort
[55–57]. The reasons why some persons are able to
quickly develop an effective cytotoxic response (ie effec-
tive CD8+ T-cell function) and others are not remain
almost a complete mystery.
As these issues are clarified, rational strategies for devel-
oping and testing novel candidate vaccines can be
formed. The ability to identify reliable surrogates of
immunity (possibly in vivo assays of CD8+ T-cell medi-
ated cytotoxicity) will be crucial to the testing of novel
vaccine candidates. Actual field trials will require huge
numbers of persons to be followed for considerable
periods of time, and are an inefficient way to screen
interesting new vaccine candidates.
If true immunity is the ability to resist infection, then it is
more accurate to state that we currently know a good deal
more about aspects of the host immune response to
tuberculosis than about genuine immunity against M tuber-
culosis. However, the work summarized in the present
review makes it possible to begin to approach a deeper
understanding of the problem.
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